Related Experiment Video
Updated: Aug 7, 2026
10:08
Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
Published on: November 22, 2024
ThromboFix platelet stabilizer: advances in clinical platelet analyses by flow cytometry?
Volker Schmidt1, Thomas Hilberg
1Department of Sports Medicine, Friedrich-Schiller-University, Jena, Germany.
Platelets
|June 14, 2006
Summary
ThromboFix stabilizes platelets for up to 7 days, enabling reliable flow cytometry analysis of platelet activation marker CD62P. However, it is not suitable for studying platelet-leukocyte conjugates.
Area of Science:
- Hematology
- Immunology
- Analytical Chemistry
Background:
- Platelet flow cytometry is challenged by spontaneous activation or fixative-induced alterations.
- Accurate analysis of platelet function requires stable, unfixed or properly stabilized samples.
Purpose of the Study:
- To evaluate the efficacy of ThromboFix, a novel platelet stabilizer, for clinical diagnostics.
- To assess ThromboFix's impact on platelet activation markers and platelet-leukocyte conjugates.
Main Methods:
- Whole blood samples were treated with ThromboFix or paraformaldehyde (PFA) with or without agonists (ADP, TRAP-6).
- Samples were stored for up to 7 days and analyzed by flow cytometry using CD41/CD62P or CD42b/CD45 antibodies.
Main Results:
- ThromboFix maintained platelet, microparticle, and aggregate stability for 7 days, unlike PFA which increased aggregation.
- ThromboFix preserved CD62P expression in resting and ADP-stimulated samples for 7 days, while PFA rapidly degraded the antigen.
- ThromboFix reduced platelet-leukocyte conjugate formation but did not stabilize pre-formed conjugates.
Conclusions:
- ThromboFix is a valuable tool for flow cytometric analysis of CD62P in clinical settings with delayed access to flow cytometers.
- ThromboFix is not recommended for investigating platelet-leukocyte conjugate formation.
